N/A N=1,906 European Sickle Cell Disease Cohort - Hydroxyurea
Sickle Cell Disease
Primary: % of Patient-years With Malignancies — 0.001 % patient-years
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=47 Retapamulin as a Decolonizing Agent for MRSA
MRSA
Primary: Number of Participants With MRSA Carriage at 1 Week Post Decolonization With Retapamulin or Placebo — 2; 13 Participants — p=0.0004
Phase 2 N=28 Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Myeloma
Primary: Primary Myeloma Endpoint — 4; 1; 1; 5 Participants
Phase 3 N=453 A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.93; -1.06 Percentage point of HbA1c — p=<.0001
Phase 3 N=731 Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR) — 51.6…
Phase 1 N=122 A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 610.1; 622.5; 1381; 1302 nanogram/milliliter (ng/mL)
Phase 3 N=40 Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
HIV
Primary: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF — 0.825 proportion of participants
N/A N=47 Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery
Atelectasis · Pulmonary Infection · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume at One Second (FEV1) Difference — 3.1; 3.1; 1.3; 1.4 Litres — p=0.88
N/A N=20 Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study
Emergence Reaction · Procedural Sedation
Primary: Emergence Reaction
Phase 4 N=30 Spinal Cord Stimulation (SCS) Dosing Study
Back Pain · Leg Pain
Primary: SCS Therapy Satisfaction — 6; 2; 1; 0 Participants
Phase 4 N=814 A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) — -2.158; -2.000 Percentage of HbA1c — p=0.1009
N/A N=91,084 Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
Depression · Preterm Delivery
Primary: Preterm Delivery — 139; 556; 272; 569 Participants
Phase 2 N=49 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
N/A N=50 EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation
Obesity, Morbid
Primary: Non Hypoxic Apnea Time — 216.7; 258.2 seconds — p=0.005
Phase 2 N=54 Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Primary: Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16 — -5.8; -75.2 percent change — p=< 0.0001